MARKET

KTTAW

KTTAW

Pasithea Therapeutics Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.0651
0.00
0.00%
Opening 16:00 06/28 EDT
OPEN
--
PREV CLOSE
0.0651
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.0618
MARKET CAP
--
P/E (TTM)
-0.3607
1D
5D
1M
3M
1Y
5Y
BRIEF-Camac Partners Llc Says Investor Group Intends To Withhold On All Of Pasithea's Sitting Directors At Upcoming Annual Meeting Of Stockholders
reuters.com · 6d ago
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
NEW YORK, June 23, 2022--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are the largest stockholder of Pasithea Therapeutics Corp...
Business Wire · 6d ago
Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurologi...
GlobeNewswire · 6d ago
BRIEF-Pasithea Therapeutics Says CFO Passed Away
reuters.com · 06/10 10:05
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurolog...
GlobeNewswire · 04/14 20:15
We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 04/05 19:57
BRIEF-Pasithea Therapeutics Announces Financial And Business Results For The Fourth Quarter
reuters.com · 03/30 20:22
Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis ---- Launched ketamine clinics in the U.K. and U.S. and ex...
GlobeNewswire · 03/30 20:15
More
No Data
Learn about the latest financial forecast of KTTAW. Analyze the recent business situations of Pasithea Therapeutics Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company. The Company is engaged on psychiatric and neurological research regarding central nervous system (CNS) disorders with focus on translating the research into clinic-ready drugs. The Company's secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician or medical providers to administer intravenous infusions of ketamine.

Webull offers kinds of Pasithea Therapeutics Corp stock information, including NASDAQ:KTTAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTAW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTTAW stock methods without spending real money on the virtual paper trading platform.